中纺标发布业绩快报，2025年营业收入1.94亿元，同比下降4.33%。净利润2153.81万元，同比下降 26.60%。受国内外宏观环境影响， 检测行业竞争加剧。报告期内，公司检测业务量虽稳步增长，但因 部分客户订单价格调整，导致营业收入有一定下滑。 ...

证券代码：300797 证券简称：钢研纳克 钢研纳克检测技术股份有限公司 投资者关系活动记录表 编号：2026-002 | | ■特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 □电话通讯 | | 参与单位名称 | 详见附件 | | 及人员姓名 | | | 活动时间 2026 | 年 2 月 26 日 | | 地点 | 钢研纳克会议室 | | 上市公司接待 | 董事会秘书 肖萍 | | 人员姓名 | 投资证券部 屈华阳 郭潇臣 周海玲 | | | 一、公司介绍 | | | 公司是专业从事金属材料检测技术的研究、开发和应用的 | | | 创新型企业。目前公司提供的主要服务或产品包括检测服务、 | | | 检测分析仪器、标准物质/标准样品、能力验证服务、腐蚀防 | | | 护工程与产品，以及其他检测延伸服务。公司的服务和产品主 | | | 要应用于钢铁、冶金、有色、机械、航空航天、高铁、核电、 | | 投资者关系活 | 汽车、新材料、环境、食品、石化等领域。 | | 动主要内容介 绍 ...

远程医疗平台Hims & Hers Health最新季度销售额上升，该公司持续扩充治疗项目范围，订阅用户数量 也有所增长。 Dudum表示，GLP‑1类药物确实为业务增长提供了显著助力，但这类药物只是其全球化消费平台中单一 领域的单一疗法，而随着持续投入，该平台正变得更加强健、多元。 他称，Hims & Hers仅有一小部分订阅用户使用复方GLP‑1类药物，这表明平台的影响力远不止于减重 领域。 他补充道，尽管并非所有新业务都能达到减重业务的增长速度，但凭借超级碗广告后用户接受度的快速 提升，公司有信心睾酮治疗、更年期护理及检测服务业务在不久的将来年营收均突破1亿美元。 "这三大新业务板块不只是新增服务，更是我们与客户建立更深度联结、创造更多价值的起点。" 尽管这家远程医疗平台预计今年增长势头将延续，但其第一季度业绩指引低于华尔街预期。 截至当日收盘，其股价在过去一年累计下跌69.8%。 这份财报发布之际，Hims & Hers正面临诺和诺德提起的诉讼，后者要求禁止该公司销售其减重药物的 仿制品。诺和诺德指控Hims & Hers侵犯司美格鲁肽相关专利，而Hims & Hers则批评该诉讼是在打压平 价药物选 ...

智通财经APP获悉，东吴证券发布研报称，当前时点，中国经济进入存量时代，但检测服务市场成长性 仍有支撑，且格局将持续优化。龙头企业强者恒强，成长空间广阔：1）AI、新能源汽车、人形机器 人、商业航天等新兴技术的发展将带来新的检测需求，并且抬高检测服务市场的门槛，2）中国产业和 经济结构的转型，将继续提高对产品品质、品牌等的要求，公信力更强的龙头企业将脱颖而出。 东吴证券主要观点如下： 检测服务行业与宏观经济增速强相关，空间大、增速稳、格局散 2024年全国检验检测市场规模约4876亿人民币，2015-2024年CAGR约10.5%。2023年以来，受宏观经济 增速放缓等影响，检验检测行业增速放缓。2025年前三季度，我国检测服务板块实现营收304亿元，同 比下降7%（剔除医学检测占比较高的金域医学、迪安诊断后，同比增长3%，增速有所放缓），龙头企 业华测检验、广电计量和苏试试验下游较为分散，品牌和服务α属性明显，2025年前三季度营收同比增 长分别为7%、12%、9%，显著领先于行业。2025年前三季度，我国检测服务板块实现归母净利润20亿 元，同比下降6%。剔除医学检测占比较高的金域医学、迪安诊断后，板块归 ...

融券方面，天溯计量2月12日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 2月12日，天溯计量跌1.07%，成交额5580.25万元。两融数据显示，当日天溯计量获融资买入额452.99 万元，融资偿还312.69万元，融资净买入140.29万元。截至2月12日，天溯计量融资融券余额合计 5477.67万元。 融资方面，天溯计量当日融资买入452.99万元。当前融资余额5477.67万元，占流通市值的5.03%。 资料显示，深圳天溯计量检测股份有限公司位于广东省深圳市龙岗区宝龙街道宝龙社区锦龙大道2号精 锭科技工业厂区1号楼1层-6层、4号楼1层-5层，成立日期2009年6月17日，上市日期2025年12月23日， 公司主营业务涉及计量校准、检测、认证等专业技术服务,客户涉及生物医药、汽车、新能源、轨道交 通、能源电力、轻工日化、装备制造等国民经济多个领域。主营业务收入构成为：计量校准服务 83.63%，检测服务16.23%，认证服务0.14%。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 ...

Group 1 - The company emphasizes its ability to leverage industry policy opportunities and has a comprehensive range of testing qualifications and extensive business layout, which supports solid business implementation and capacity release [2] - The company's operating performance has shown steady growth in recent years, with all operational data accurately reflecting its development achievements, countering claims of "paper data" [2] - As a leading enterprise in the industry, the company focuses on enhancing operational efficiency, accelerating the release of emerging businesses, and strengthening internal collaboration to create differentiated advantages [2] Group 2 - The company is successfully converting industry dividends into operational effectiveness and asserts that it does not underperform relative to the industry average [2] - The capital market performance is influenced by multiple factors, including macroeconomic conditions and market sentiment, and short-term fluctuations do not represent the company's long-term value [2] - The company encourages rational perspectives on market volatility and advises caution regarding investment risks [2]

Core Viewpoint - The company, Poni Testing (300887), aims to focus on high-potential sectors by 2026, benefiting from policy-driven growth in testing demand, which is expected to improve its financial performance [1]. Business Progress - The company plans to deepen its engagement with major clients in 2026, emphasizing sectors such as biomedicine, new energy vehicles, low-altitude economy, and specialized industry testing to enhance laboratory capacity utilization and operational efficiency [2]. - With the optimization of its client structure, revenue is anticipated to gradually return to normal levels [2]. Industry Policy and Environment - The implementation of the electric passenger vehicle export license management policy starting January 2026 is expected to increase testing demand [3]. - The company is transitioning from a single testing service provider to a comprehensive role that includes quality solutions and technical consulting for automotive companies, aiding them in meeting overseas market compliance requirements [3]. Current Operating Status - Despite an expected loss of 200 to 250 million yuan for the full year of 2025, the company is striving to reduce losses through cost-cutting and management optimization [4]. - The net profit attributable to the parent company for the third quarter of 2025 has improved by 69.40% year-on-year, with future attention needed on the 2025 annual report and 2026 quarterly performance to see if the improvement trend continues [4]. Recent Stock Performance - The stock price was previously boosted by concepts like commercial aerospace, but the company announced no undisclosed significant changes [5]. - Investors are advised to be cautious of short-term volatility risks and to monitor actual order progress and capacity release [5].

Core Insights - Steel Research Nack (300797) has shown double-digit growth in both revenue and net profit according to its Q3 2025 report, despite experiencing a net outflow of main funds on February 10, 2026 [1][3]. Stock Performance - On February 10, 2026, Steel Research Nack's stock closed at 18.35 CNY, down 0.49% with a net outflow of 4.78 million CNY from main funds, while retail investors contributed a net inflow of 6.67 million CNY. The trading volume reached 79.13 million CNY with a turnover rate of 1.14%. As of February 11, 2026, the stock price was 18.23 CNY, reflecting a 0.65% decline from the previous day, with a cumulative increase of 0.77% over the past five days and a volatility of 1.80% [2]. Financial Report Analysis - The Q3 2025 report revealed that Steel Research Nack's main revenue for the first three quarters was 806 million CNY, marking an 11.64% year-on-year increase. The net profit attributable to shareholders was approximately 99.70 million CNY, up 15.08% year-on-year, with a gross margin of 46.98%, an increase of 1.03 percentage points. In Q3 alone, revenue was 307 million CNY, reflecting a 15.77% year-on-year growth, and the growth rate of net profit excluding non-recurring items reached 21.19%. R&D expenses increased by 23.06% year-on-year, primarily directed towards high-end scientific instruments and new testing technologies [3]. Institutional Perspectives - In the past 90 days, one institution has rated Steel Research Nack as a "buy" with a target average price of 21.15 CNY. During the research, the company emphasized the stability of its core technical personnel, with the testing business accounting for approximately 50% of its operations, while the instrument segment is accelerating its high-end breakthroughs [4].

Group 1 - The core viewpoint of the news is that Tian Su Measurement has shown a positive performance in terms of stock price and financial metrics, indicating potential growth opportunities in the measurement and testing industry [1][2]. - On February 10, Tian Su Measurement's stock price increased by 2.28%, with a trading volume of 137 million yuan. The financing buy-in amount was 9.83 million yuan, while the financing repayment was 10.68 million yuan, resulting in a net financing buy-in of -0.85 million yuan [1]. - As of February 10, the total balance of margin trading for Tian Su Measurement was 56.28 million yuan, accounting for 5.01% of its circulating market value [1]. Group 2 - As of January 30, the number of shareholders for Tian Su Measurement was 17,400, a decrease of 13.84% compared to the previous period. The average circulating shares per person increased by 16.06% to 799 shares [2]. - For the period from January to September 2025, Tian Su Measurement achieved an operating income of 648 million yuan, representing a year-on-year growth of 12.12%. The net profit attributable to the parent company was 92.99 million yuan, with a year-on-year increase of 11.62% [2]. - The company specializes in measurement calibration, testing, and certification services, with its main business revenue composition being 83.63% from calibration services, 16.23% from testing services, and 0.14% from certification services [1].

Group 1 - The core viewpoint of the news is that Tian Su Measurement has shown a slight increase in stock price and has reported specific financial metrics related to its financing activities and business performance [1][2]. Group 2 - On February 9, Tian Su Measurement's stock price increased by 0.68%, with a trading volume of 61.68 million yuan. The financing buy-in amount was 3.09 million yuan, while the financing repayment was 5.61 million yuan, resulting in a net financing buy-in of -2.52 million yuan. The total financing and securities balance reached 57.13 million yuan [1]. - As of February 9, the financing balance of Tian Su Measurement was 57.13 million yuan, accounting for 5.21% of its circulating market value [1]. - The company is located in Shenzhen, Guangdong Province, and was established on June 17, 2009. It specializes in measurement calibration, testing, and certification services across various sectors, including biomedicine, automotive, new energy, and rail transportation [1]. - For the period from January to September 2025, Tian Su Measurement achieved an operating income of 648 million yuan, representing a year-on-year growth of 12.12%. The net profit attributable to the parent company was 92.99 million yuan, with a year-on-year increase of 11.62% [2]. - As of January 30, the number of shareholders of Tian Su Measurement was 17,400, a decrease of 13.84% from the previous period, while the average circulating shares per person increased by 16.06% to 799 shares [2].